VivoSeq
Infectious Disease

Pneumococcal Pneumonia

3

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Pneumococcal Pneumonia is an early-stage landscape with 3 programs across 1 company. The most active players are Pfizer. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

0/100

Attrition Rate

100/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved3

Linezolid

Pfizer

Ceftriaxone

Conrado Roberto Hoffmann Filho

Levofloxacin

Wim Janssens

Analysis

Trial Status

1

clinical trials

Terminated1 · 100%

Clinical Trials

Trial Activity

Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia
Terminated·HHospital Mutua de Terrassa·Phase 4·NCT00429975·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)